Sugi Predict

Sugi Predict / Compounds / SCHEMBL29548987

SCHEMBL29548987

SCHEMBL29548987

COc1ccc(C(C(=O)[C@@H](CCCNC(=N)N)NC(=O)OC(C)(C)C)(c2ccccc2)c2ccc(OC)cc2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CTSK P43235 7/20 0.43
▸ PPARG P37231 2/20 0.43
▸ PPARA Q07869 2/20 0.43
▸ JAK3 P52333 1/20 0.43
▸ BTK Q06187 1/20 0.43
▸ CXCR3 P49682 1/20 0.42
▸ CTSS P25774 4/20 0.40
▸ HDAC4 P56524 2/20 0.40
▸ HDAC1 Q13547 2/20 0.40
▸ KIF11 P52732 1/20 0.39
▸ MMP2 P08253 2/20 0.39
▸ MMP9 P14780 2/20 0.39
▸ CTSL P07711 1/20 0.39
▸ CTSB P07858 1/20 0.39
▸ HDAC3 O15379 1/20 0.39
▸ HDAC7 Q8WUI4 1/20 0.39
▸ HDAC2 Q92769 1/20 0.39
▸ HDAC10 Q969S8 1/20 0.39
▸ HDAC11 Q96DB2 1/20 0.39
▸ HDAC8 Q9BY41 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29549032 0.82 KIF11 (0.50) HDAC1KIF11HDAC7ITGB3ITGA2B
SCHEMBL29549080 0.82 KIF11 (0.50) HDAC1KIF11HDAC7ITGB3ITGA2B
SCHEMBL31034866 0.82 KIF11 (0.50) HDAC1KIF11HDAC7ITGB3ITGA2B
SCHEMBL30632162 0.81 JAK3 (0.41) CTSKPPARGPPARAJAK3BTK
SCHEMBL29964865 0.78 KIF11 (0.46) KIF11ITGB3ITGA2B
SCHEMBL27118429 0.77 CTSK (0.59) CTSKJAK3BTKCTSSMMP9
SCHEMBL31637596 0.77 NPSR1 (0.49) CTSKPPARGPPARACXCR3ALDH1A1
SCHEMBL1486276 0.77 MEN1 (0.55) CTSKPPARGPPARAJAK3BTK
SCHEMBL7364210 0.77 MEN1 (0.55) CTSKPPARGPPARAJAK3BTK
SCHEMBL2367531 0.77 MEN1 (0.55) CTSKPPARGPPARAJAK3BTK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250002531-A1 PROCESSES FOR PREPARING PHARMACEUTICALLY RELEVANT PEPTIDES STEALTH BIOTHERAPEUTICS INC. (US) 2025-01-02 — — US claimed
US-12037414-B2 Processes for preparing pharmaceutically relevant peptides STEALTH BIOTHERAPEUTICS INC. (US) 2024-07-16 — — US claimed
EP-4725506-A2 THE PEPTIDOMIMETIC COMPOUND (R)-2-AMINO-N-((S)-L-(((S)-5-AMINO-L-(3-BENZYL-1,2,4-OXADIAZOL-5-YL)PENTYL)AMINO)-3-(4-HYDROXY-2,6-DIMETHYLPHENYL)-1-OXOPROPAN-2-YL)-5-GUANIDINOPENTANAMIDE FOR USE IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS Stealth BioTherapeutics Inc. (US) 2026-04-15 — — EP disclosed
EP-3986401-B1 THE PEPTIDOMIMETIC COMPOUND (R)-2-AMINO-N-((S)-L-(((S)-5-AMINO-L-(3-BENZYL-1,2,4-OXADIAZOL-5-YL)PENTYL)AMINO)-3-(4-HYDROXY-2,6-DIMETHYLPHENYL)-1-OXOPROPAN-2-YL)-5-GUANIDINOPENTANAMIDE FOR USE IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS STEALTH BIOTHERAPEUTICS INC (US) 2026-01-28 — — EP disclosed
US-20250122238-A1 CRYSTALLINE DIPEPTIDES USEFUL IN THE SYNTHESIS OF ELAMIPRETIDE STEALTH BIOTHERAPEUTICS INC. 2025-04-17 — — US disclosed
US-20250122238-A1 CRYSTALLINE DIPEPTIDES USEFUL IN THE SYNTHESIS OF ELAMIPRETIDE STEALTH BIOTHERAPEUTICS INC. 2025-04-17 — — US disclosed
US-20250002531-A1 PROCESSES FOR PREPARING PHARMACEUTICALLY RELEVANT PEPTIDES STEALTH BIOTHERAPEUTICS INC. (US) 2025-01-02 — — US disclosed
CN-118725014-A Mitochondrial targeting peptides 隐形生物治疗公司 2024-10-01 — — CN disclosed
CN-118702766-A Mitochondrial targeting peptides 隐形生物治疗公司 2024-09-27 — — CN disclosed
CN-118702767-A Mitochondrial targeting peptides 隐形生物治疗公司 2024-09-27 — — CN disclosed
EP-4419123-A1 METHODS AND COMPOSITIONS COMPRISING PEPTIDOMIMITICS FOR TREATING, PREVENTING, INHIBITING, AMELIORATING OR DELAYING THE ONSET OF OPHTHALMIC CONDITIONS Stealth BioTherapeutics Inc. (US) 2024-08-28 — — EP disclosed
WO-2023069549-A1 METHODS AND COMPOSITIONS COMPRISING PEPTIDOMIMITICS FOR TREATING, PREVENTING, INHIBITING, AMELIORATING OR DELAYING THE ONSET OF OPHTHALMIC CONDITIONS STEALTH BIOTHERAPEUTICS INC. (US) 2023-04-27 — — WO disclosed
EP-3774844-B1 CRYSTALLINE DIPEPTIDES USEFUL IN THE SYNTHESIS OF ELAMIPRETIDE STEALTH BIOTHERAPEUTICS INC (US) 2023-02-22 — — EP disclosed
EP-3723783-B1 MITOCHONDRIA-TARGETING PEPTIDES STEALTH BIOTHERAPEUTICS INC (US) 2023-02-15 — — EP disclosed
US-11560404-B2 Crystalline dipeptides useful in the synthesis of elamipretide STEALTH BIOTHERAPEUTICS INC. (US) 2023-01-24 — — US disclosed
US-11560404-B2 Crystalline dipeptides useful in the synthesis of elamipretide STEALTH BIOTHERAPEUTICS INC. (US) 2023-01-24 — — US disclosed
US-20220265615-A1 Compositions and Methods for the Treatment of Amyotrophic Lateral Sclerosis, Parkinson?s Disease, Parkinson?s Disease with Dementia, Dementia with Lewy Bodies, and Multiple System Atrophy STEALTH BIOTHERAPEUTICS INC. (US) 2022-08-25 — — US disclosed
CN-114466656-A Peptidomimetic compounds (R) -2-amino-N- ((S) -1- (((S) -5-amino-1- (3-benzyl-1, 2, 4-oxadiazol-5-yl) pentyl) amino) -3- (4-hydroxy-2, 6-xylyl) -1-oxopropan-2-yl) -5-guanidinopentanamide in the treatment of neurodegenerative disorders 康德生物医疗有限公司 2022-05-10 — — CN disclosed
EP-3986401-A1 THE PEPTIDOMIMETIC COMPOUND (R)-2-AMINO-N-((S)-L-(((S)-5-AMINO-L-(3-BENZYL-1,2,4-OXADIAZOL-5-YL)PENTYL)AMINO)-3-(4-HYDROXY-2,6-DIMETHYLPHENYL)-I-OXOPROPAN-2-YL)-5-GUANIDINOPENTANAMIDE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES Stealth BioTherapeutics Inc. (US) 2022-04-27 — — EP disclosed
US-11273149-B2 Compositions and methods for the treatment of amyotrophic lateral sclerosis, Parkinson's disease, Parkinson's disease with dementia, dementia with Lewy bodies, and multiple system atrophy STEALTH BIOTHERAPEUTICS INC. (US) 2022-03-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250002531-A1 PROCESSES FOR PREPARING PHARMACEUTICALLY RELEVANT PEPTIDES ADM2, VIP, PEPD CTSK 912/4885PPARG 3835/4885PPARA 3484/4885
US-20250122238-A1 CRYSTALLINE DIPEPTIDES USEFUL IN THE SYNTHESIS OF ELAMIPRETIDE PEPD, DPP4, ANPEP CTSK 353/4885PPARG 2089/4885PPARA 1118/4885
US-11560404-B2 Crystalline dipeptides useful in the synthesis of elamipretide PEPD, DPP4, ANPEP CTSK 353/4885PPARG 2089/4885PPARA 1118/4885
US-12037414-B2 Processes for preparing pharmaceutically relevant peptides ADM2, VIP, PEPD CTSK 912/4885PPARG 3835/4885PPARA 3484/4885
US-20220265615-A1 Compositions and Methods for the Treatment of Amyotrophic Lateral Sclerosis, Parkinson?s Disease, Parkinson?s Disease with Dementia, Dementia with Lewy Bodies, and Multiple System Atrophy NLN, TARDBP, PARK7 CTSK 2427/4885PPARG 1526/4885PPARA 801/4885
US-11273149-B2 Compositions and methods for the treatment of amyotrophic lateral sclerosis, Parkinson's disease, Parkinson's disease with dementia, dementia with Lewy bodies, and multiple system atrophy NLN, TARDBP, PARK7 CTSK 2459/4885PPARG 1418/4885PPARA 797/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.